Put the Efficacy and Safety of Overactive Bladder Meds Into Perspective

May 2017

There will be a shift toward fewer Rxs for immediate-release oxybutynin for overactive bladder.

Many payers used to require trying oxybutynin IR before covering any other antimuscarinics...since they tended to cost more.

But costs are coming down as more of these meds go generic.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote